<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Polymethylmethacrylate microspheres soft tissue filler: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Polymethylmethacrylate microspheres soft tissue filler: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Polymethylmethacrylate microspheres soft tissue filler: Drug information</div><div class="clear"></div><div id="topicText">For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F55499122"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Bellafill</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F50470903"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Cosmetic Agent, Implant</li></ul></div>
<div class="block doa drugH1Div" id="F50472341"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>A skin test should be performed 4 weeks prior to treatment. Refer to the manufacturer's instructions for use for additional information on the interpretation of skin test results.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1dac6209-568b-48f5-9f2c-a7cfedde732b">Nasolabial folds and facial acne scars</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nasolabial folds and facial acne scars:</b> Intradermal: ≥21 years: Inject as needed for cosmetic result; injecting &gt;3.5 mL per treatment site or 8.9 mL overall has not been established. Correction should be limited to no more than 100% of the skin defect during treatment. One or two touch-up implantations at intervals of at least 2 weeks may be required to achieve the desired effect.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50992122"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50989358"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F50472342"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F46041849"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Incidences reported with acne scar treatment unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Fatigue (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Contact dermatitis (1%), pruritus (nasolabial fold [NLF] and acne scars: ≤1%; NLF: Occurred &gt;48 hours after injection, duration ranged from 3 weeks to &gt;3 months), skin rash (NLF and acne scars: ≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hyperesthesia (NLF: 2%; duration ranged from 4 weeks to unresolved at 26 weeks)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Residual mass at injection site (NLF: 5% [1 month postinjection; duration ranged from 4 weeks to unresolved at 26 weeks], acne scars: &lt;1% [many patients reported residual lumps/bumps up to 2 weeks postinjection]), injection site reaction (4%), tenderness at injection site (acne scars: 4%, NLF: &lt;1% [occasional]), erythema at injection site (NLF: ≤4% [duration ranged from 5 weeks to unresolved at 26 weeks], acne scars: &lt;1% [many patients reported erythema up to 2 weeks postinjection]), swelling at injection site (NLF and acne scars: ≤4%; NLF: duration ranged from 5 weeks to unresolved at 26 weeks), bruising at injection site (2%; many patients reported bruising up to 2 weeks postimplantation), pain at injection site (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (3%), sinusitis (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abscess, acneiform eruption, acne vulgaris, actinic keratosis, areata alopecia (NLF; some occurrences reported ≥3 months after injection), atopic dermatitis, bacterial infection, blurred vision, burning sensation, chest congestion (mild), cutaneous papilloma, exacerbation of herpes labialis, flu-like symptoms, granuloma (NLF; duration ranged from 10 weeks to unresolved at 26 weeks), herpes zoster, hordeolum, implant-site complication (NLF; enlargement of implant; duration ranged from 10 weeks to unresolved at 26 weeks), influenza, limb pain, meningitis, otic infection, pharyngitis, puncture wound (NLF; puncture area visible; duration 13 weeks), seborrheic dermatitis, skin discoloration at injection site, squamous cell carcinoma of skin, syncope, telangiectasia (NLF; occasional, some occurrences reported ≥3 months postinjection), xeroderma</p></div>
<div class="block coi drugH1Div" id="F50470909"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to polymethylmethacrylate, lidocaine, bovine collagen, or any component of the formulation; positive response to Bellafill Skin test; patients with severe allergies manifested by a history of anaphylaxis or history or presence of multiple severe allergies; patients undergoing or planning to undergo desensitization injections to meat products; patients with bleeding disorders; patients with susceptibility to keloid formation or hypertrophic scarring; use for lip augmentation and injection into the vermilion or the wet mucosa of the lip.</p></div>
<div class="block war drugH1Div" id="F50471042"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects: </i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Intravascular injection: Inadvertent intravascular injection of dermal fillers may cause embolization, vessel occlusion, ischemia, or infarction resulting in vision impairment or blindness, cerebral hemorrhage or ischemia, skin necrosis, and damage to underlying facial structures. Treatment should be discontinued and patient promptly evaluated if exhibiting any signs or symptoms of intravascular injection.</p>
<p style="text-indent:-2em;margin-left:4em;">• Skin effects: Hyperpigmentation, keloid formation, or hypertrophic scars may occur after dermal filler injections.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acne scars: Safety and effectiveness have not been established in patients with non-distensible atrophic acne scars, ice pick scars, or sinus tract scars.</p>
<p style="text-indent:-2em;margin-left:4em;">• Connective tissue disorder: Safety has not been established in patients with connective tissue disorder. Use with caution; may have increased hypersensitivity response and/or accelerated clearance of implants. Further skin testing may be necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anticoagulant/antiplatelet agents: Use within 3 weeks after administration has not been studied.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunosuppressive therapy: Concomitant use with immunosuppressive therapy has not been established. Use with caution; may have increased hypersensitivity response and/or accelerated clearance of implants. Further skin testing may be necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• Other dermal response procedures: Laser treatment, chemical peeling, or similar procedures may elicit an inflammatory response at injection site.</p>
<p style="text-indent:-2em;margin-left:4em;">• Other wrinkle therapies: Use within 6 months of other wrinkle therapies (eg, collagen, botulinum toxin) has not been studied.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate administration: Dermal fillers, including polymethylmethacrylate, should be administered using a syringe with a needle or cannula. Needle-free devices for injection of dermal fillers are not FDA-approved and may cause serious injuries or permanent harm to the skin, lips, or eyes. FDA-approved dermal fillers should not be transferred into needle-free injection devices (FDA Safety Communication 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not indicated for use in the periocular area; granulomas, lumps, swelling, and vision loss due to vascular occlusion have been reported with off-label injection into the periocular area.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cold weather: Exposure to extreme cold weather should be minimized until initial swelling and redness have resolved.</p>
<p style="text-indent:-2em;margin-left:4em;">• Photosensitivity: Excessive exposure to sun or UV lamp should be minimized until initial swelling and redness have resolved.</p>
<p style="text-indent:-2em;margin-left:4em;">• Skin inflammation or infection: Treatment should be deferred if active inflammation (eg, cysts, pimples, rash, hives) or infection present at injection site(s).</p>
<p style="text-indent:-2em;margin-left:4em;">• Skin testing: Skin testing must be performed; patients with a positive test, two equivocal tests, or demonstrating an anti-bovine collagen serum IgG level outside the normal range at baseline should not be treated.</p></div>
<div class="block foc drugH1Div" id="F55499123"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;">Implant, dermal:</p>
<p style="text-indent:-2em;margin-left:4em;">Bellafill: Polymethylmethacrylate microspheres 20% and lidocaine 0.3% [contains bovine collagen]</p></div>
<div class="block adm drugH1Div" id="F50472353"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Bring syringe to room temperature before injection. Injection area should be washed with soap and water then cleaned with alcohol or other antiseptic. Refer to manufacturer's instructions for use for comprehensive administration information.</p></div>
<div class="block use drugH1Div" id="F50470905"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Nasolabial folds and facial acne scars</b>
<b>: </b> Correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on the cheek in patients 21 years and older.</p></div>
<div class="block cyt drugH1Div" id="F45525301"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F45525298"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Polymethylmethacrylate. Specifically, the risk for hypersensitivity or implant clearance may be increased. Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccine (mRNA): May enhance the adverse/toxic effect of Dermal Fillers. Specifically, the risk for swelling at or near the site of dermal filler injection (usually face or lips) may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): May enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate. Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): May enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate. Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): May enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate. Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate. Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving methotrexate. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54208208"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Women of reproductive potential not using effective contraception were excluded from initial studies (Cohen 2004; Joseph 2015).</p></div>
<div class="block pri drugH1Div" id="F50470906"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Pregnant women were excluded from initial studies (Cohen 2004; Joseph 2015).</p></div>
<div class="block brc drugH1Div" id="F50470907"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Breastfeeding women were excluded from initial studies (Cohen 2004; Joseph 2015).</p></div>
<div class="block pha drugH1Div" id="F50472326"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">After implantation, the bovine collagen component dissipates over the course of 1 to 3 months, leaving behind the nonbiodegradable PMMA microspheres. The microspheres stimulate a local inflammatory reaction that is followed by the deposition of granulation tissue during the first few weeks after implantation. The connective tissue subsequently matures, and by three months after injection, PMMA microspheres are surrounded by newly formed collagen. The presence of new collagen accounts for the observed volume-filling effect (Cohen 2004; Lemperle 2010).</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Bellafill (polymethylmethacrylate) [prescribing information]. San Diego, CA: Suneva Medical Inc; July 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15468406">
<a name="15468406"></a>Cohen SR, Holmes RE. Artecoll: a long-lasting injectable wrinkle filler material: Report of a controlled, randomized, multicenter clinical trial of 251 subjects. <i>Plast Reconstr Surg</i>. 2004;114(4):964-976; discussion 977-979.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymethylmethacrylate-microspheres-soft-tissue-filler-drug-information/abstract-text/15468406/pubmed" id="15468406" target="_blank">15468406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26441096">
<a name="26441096"></a>Joseph JH, Eaton LL, Cohen SR. Current concepts in the use of Bellafill. <i>Plast Reconstr Surg</i>. 2015;136(5 suppl):171S-179S.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymethylmethacrylate-microspheres-soft-tissue-filler-drug-information/abstract-text/26441096/pubmed" id="26441096" target="_blank">26441096</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19787394">
<a name="19787394"></a>Lemperle G, Knapp TR, Sadick NS, Lemperle SM. ArteFill permanent injectable for soft tissue augmentation: I. Mechanism of action and injection techniques. <i>Aesthetic Plast Surg</i>. 2010;34(3):264-272. doi:10.1007/s00266-009-9413-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/polymethylmethacrylate-microspheres-soft-tissue-filler-drug-information/abstract-text/19787394/pubmed" id="19787394" target="_blank">19787394</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration (FDA). FDA drug safety communication: do not use needle-free devices for injection of dermal fillers. <a href="https://www.fda.gov/medical-devices/safety-communications/do-not-use-needle-free-devices-injection-dermal-fillers-fda-safety-communication" target="_blank">https://www.fda.gov/medical-devices/safety-communications/do-not-use-needle-free-devices-injection-dermal-fillers-fda-safety-communication</a>. Published October 8, 2021. Accessed October 19, 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 114509 Version 21.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
